BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX Announces $25 Million Patent License Agreement

MiMedx (MDXG)MiMedxPartnership

MARIETTA, Ga., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into a license agreement with a wound care competitor that resolves allegations of infringement of MIMEDX’s patents.

Related news

MDXGMiMedx2026-11-06 13:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

ALVOAlvotech2026-10-06 20:37 EST

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

RXRXRecursion2026-10-15 12:45 EST

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

ADMAADMA Biologics2026-03-02 12:00 EST

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

RXRXRecursion2026-10-15 12:30 EST

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-11-06 13:00 EST

MIMEDX to Participate in Upcoming Investor Conferences

MDXGMiMedx2026-10-28 20:03 EST

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-10-28 20:01 EST

MIMEDX Announces $25 Million Patent License Agreement

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MDXGMiMedx2026-09-23 20:01 EST

MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter

Stock data

Close
3.28 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States